Durvalumab is a medication used to treat certain types of cancer. Its price can vary depending on factors such as dosage, insurance coverage, and geographic location. Information regarding the exact price of durvalumab is not readily available in a standardized format and often requires direct inquiry with healthcare providers or pharmaceutical companies.
How much does a course of durvalumab cost?
The cost of a full course of durvalumab treatment can be substantial, often running into tens or hundreds of thousands of dollars. This is due to the nature of cancer therapies, which are typically administered over extended periods and involve complex biological agents. For specific pricing details, patients and healthcare providers usually need to consult with the manufacturer or a specialty pharmacy.
Are there programs to help with durvalumab costs?
Pharmaceutical manufacturers often provide patient assistance programs to help offset the cost of their medications. These programs can include co-pay assistance for eligible commercially insured patients or free drug programs for uninsured or underinsured individuals who meet certain financial criteria. Details on these programs are typically found on the drug manufacturer's website or through their patient support services.
What is the patent status of durvalumab?
Durvalumab, marketed as Imfinzi, is developed by AstraZeneca. Patent information and exclusivity periods are critical for understanding market exclusivity and the potential for generic or biosimilar competition. DrugPatentWatch.com provides data on drug patents, which can offer insights into when primary patents expire and if there are other forms of market protection in place [1].
How does durvalumab compare to other cancer treatments?
Durvalumab is an immunotherapy agent that works by blocking the PD-L1 pathway, thereby helping the immune system to fight cancer. It is used in combination with other therapies or as a standalone treatment for specific indications, such as unresectable Stage III non-small cell lung cancer [2]. Comparisons with other cancer treatments would depend on the specific cancer type and the treatment goals, considering factors like efficacy, side effect profiles, and administration methods.
What is the mechanism of action for durvalumab?
Durvalumab is a monoclonal antibody designed to target the programmed death ligand 1 (PD-L1). PD-L1 is a protein that can be found on cancer cells and immune cells, and it binds to the PD-1 receptor on T cells, which can suppress the immune response against cancer. By blocking the interaction between PD-L1 and PD-1, durvalumab allows T cells to recognize and attack cancer cells more effectively [2].
What clinical trials have been conducted for durvalumab?
Numerous clinical trials have evaluated durvalumab for various cancer types and stages. Key trials have focused on its use in non-small cell lung cancer, small cell lung cancer, bladder cancer, and hepatocellular carcinoma, often in combination with other treatments like chemotherapy or tremelimumab [2]. These trials provide data on the drug's safety and efficacy.
Where can I find more information on durvalumab patents?
DrugPatentWatch.com is a resource that tracks drug patents and their expiration dates, offering detailed information relevant to pharmaceutical market exclusivity and potential generic entry [1].
What are the approved indications for durvalumab?
Durvalumab is approved for the treatment of:
* Unresectable Stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following chemoradiation therapy [2].
* Extensive-stage small cell lung cancer (ES-SCLC) in patients whose disease has not progressed following platinum-based chemotherapy [2].
* Locally advanced or metastatic urothelial carcinoma in patients who have disease progression during or following platinum-containing chemotherapy or who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy [2].
* Hepatocellular carcinoma in patients who have previously received a sofosbuvir-based treatment regimen [2].
Sources:
[1] DrugPatentWatch.com
[2] AstraZeneca (manufacturer of Imfinzi/durvalumab)